
Shares of U.S. drugmaker Eli Lilly LLY.N up 3.3% at $1,072.44
Lilly says its oral pill, orforglipron, helps maintain weight loss in patients switching from injectable versions of GLP-1 drugs
In the late-stage trial, patients who took orforglipron for 52 weeks, after an initial treatment period of 72 weeks with Wegovy or Zepbound, showed superior weight maintenance compared to placebo
An oral weight-loss pill would help Lilly further widen its lead over Novo Nordisk NOVOb.CO
Up to last close, LLY up 35% YTD